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Abstract Normal micelle microemulsion method was uti-
lized for fabrication of organically modified silica
(ORMOSIL) nanoparticles. The void and dye-doped
nanoparticles were synthesized in nonpolar core of two dif-
ferent surfactants including Aerosol OT and Tween 80. The
nanoparticles were characterized using transmission electron
microscopy, dynamic light scattering, and zeta potential anal-
ysis. Our results revealed that the type of surfactant molecules
has a dramatic impact on the size and size distribution range,
surface charge, and surface functionalization of the
nanoparticles. The particles fabricated using Tween 80 had
very smaller size with narrow size distribution and very lower
amount of zeta potential. For specific delivery of functional-
ized nanoparticles to breast cancer cell line SKBR3,
overexpressing human epidermal growth factor receptor 2
(HER2), both dye-doped nanoparticles fabricated with
Aerosol OT or Tween 80, was conjugated to Herceptin. In
vitro studies using fluorescent microscopy demonstrated that
the surfactant used for preparation of the nanoparticles can
affect the uptake of the particles by cells. The dye-doped
functionalized ORMOSIL nanoparticles prepared with
Aerosol OT showed better efficiency in the process of active
targeting of HER2 receptor. Herceptin-functionalized
ORMOSIL nanoparticles can be used for differentiation of
HER2-positive from HER2-negative breast cancer cells or
specific delivery of therapeutic and diagnostic agents and also
other nanoparticles such as magnetic nanoparticles and quan-
tum dots to breast cancer cells.
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1 Introduction
There are two various approaches for targeting tumor cells
using nanoparticles: (1) passive targeting through the en-
hanced permeability and retention effect (Danhier et al.
2010) that takes advantage of special characteristics of tu-
mors: angiogenesis, leaky vessels, poor lymphatic system,
and results in passive accumulation of nanoparticles to
tumor sites; (2) active targeting that takes advantage of
overexpression of specific proteins and receptors in cancer
cells, such as human epidermal receptor (HER) or transfer-
rin and folate receptors, for enhanced delivery of targeting
moiety-conjugated nanoparticles. This results in high local
concentrations of nanoparticles on the surface of the cancer
cells or internalization of nanoparticles into the cancer cells,
depending on the type of selected biomoiety and its
receptors. The second approach is very promising for
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specific and selective delivery of therapeutic and diag-
nostic agents with better efficacy and lower toxicity
(Byrne et al. 2008; Gu et al. 2007).
Among a family of four transmembrane epidermal growth
factor receptor tyrosine kinases including HER1 to HER4
(Harries and Smith 2002), HER2 is highly overexpressed on
25 to 30 % of human breast cancer cells as well as some other
human tumors including lung and ovarian carcinomas (Slamon
et al. 1987;Witton et al. 2003). Hence, one of themost common
approaches for breast cancer cells targeting has been using
HER2-specific antibodies (Colombo et al. 2010). Herceptin or
trastuzumab is a humanized monoclonal antibody against
HER2 receptors approved as a drug by FDA in 1998 and is
now used in metastatic breast tumors (Slamon et al. 2001).
Organically modified silica (ORMOSIL) nanoparticles
are a kind of silica nanoparticles that are ultrasmall, mono-
disperse, spherical, mesoporous, and surface modified with
an organosilane molecule such as (3-aminopropyl)
triehoxysilane (APTES) (Yong et al. 2009; Qian et al.
2010). There are two main approaches for fabrication of
silica nanoparticles including the Stöber method (Stober et
al. 1968) as well as microemulsion processes either reverse
micelle (Osseo-Asare and Arriagada 1990) or normal mi-
celle (Roy et al. 2003). Typically, ORMOSIL nanoparticles
are synthesized using normal micelle microemulsion
procedure in which the self-assembled nanoreactors
produced in an oil-in-water microemulsion system are used
as surrounded microenvironments for hydrolysis and
condensation of organosilane molecules such as
Triethoxyvinylsilane (VTES) (Ciriminna et al. 2011; Yong
et al. 2009). These nanoparticles have a number of advan-
tages particularly for biomedical applications. Similar to
other silica-based materials, ORMOSIL nanoparticles are
inert and compatible with bioenvironments and biomole-
cules such as enzymes (Ciriminna et al. 2011). Since the
particles have very small size range with narrow size distri-
bution (10–50 nm), they are hidden from reticuloendothelial
system, therefore capable for using in vivo (Roy et al. 2003).
Moreover, these nanoparticles are transparent to light and
very fascinating for applying in nanobiophotonics such as
photodynamic therapy (Ohulchanskyy et al. 2007; Kim et al.
2007a, 2009) and optical bioimaging (Kim et al. 2007b;
Kumar et al. 2008; Law et al. 2008; Qian et al. 2008;
2009; Wang et al. 2008). It is feasible to incorporate organic
molecules such as organic dyes (Qian et al. 2008; Bagwe et
al. 2004) and other nanoparticles such as quantum dots
(Qian et al. 2009; Darbandi et al. 2005) or gold
nanoparticles (Han et al. 2008) or even a combination of
different nanoparticles (Bardhan et al. 2009; Viswanathan
2011) into the silica matrix. This strategy is a wise consid-
eration to collect common beneficial characteristics of
silica particles such as transparency, biocompatibility, and
functionalizability with special properties of other
nanoparticles such as photostability of quantum dots or
thermal properties of gold nanoparticles.
Over the past decade, ORMOSIL nanoparticles have been
developed by N. Prasad’s group and other groups. They have
applied Aerosol OT (AOT) and Tween 80 micellar systems in
order to synthesis the nanoparticles (Roy et al. 2003; Kumar et
al. 2008) and applied different targeting moieties for conjuga-
tion to the nanoparticles. To demonstrate the potential of
ORMOSIL nanoparticles for bioconjugation, Kumar et al.
functionalized the surface of the nanoparticles with various
active groups and conjugated with different biomoieties and
showed active targeting (Kumar et al. 2008). They also con-
jugated the nanoparticles with iodine-124, a positron emission
tomographic imaging probe, and showed biodistribution of
the nonspecific conjugated nanoparticles (Kumar et al. 2010).
Qian et al. (2008) showed specific cellular uptake of amino
group-functionalized ORMOSIL nanoparticles encapsulated
with an organic dye and conjugated with apo-transferrin and
folic acid in HeLa cells. Wang et al. used folate receptor
functionalized ORMOSI nanoparticles entrapped a hydropho-
bic two-photon absorbing fluorenyl dye for two-photon fluo-
rescence microscopy bioimaging in vitro. To confirm active
targeting of nanoparticles, they applied HeLa cells and MG63
cells as high and low folate receptor expressing cell lines,
respectively (Wang et al. 2008).
The surface modification of nanoparticles plays a critical
role to provide novel properties and functionalities for the
nanoparticles. In terms of ORMOSIL nanoparticles, the sur-
face can be modified with various functional groups such as
amine and carboxyl simply by replacing the organosilane
precursor. The surface properties of silica particles plays a
significant role in the interaction of the particles with
bioenvironments (Nel et al. 2009) and determines the cellular
uptake (Xia et al. 2009) and cytotoxicity (Nabeshi et al. 2011;
Morishige et al. 2010) of the resulting particles. Moreover, the
produced functional groups through surface functionalization
can increase colloidal stability of the particles and can be
utilized for conjugation to different biomoieties for targeting
and specific gene/drug delivery to various cancerous cells
(Klejbor et al. 2007; Bharali et al. 2005). The remained sur-
factant molecules on the surface of ORMOSIL nanoparticles
synthesized by microemulsion method can affect their surface
charge, surface functionalization, cellular uptake, and cytotox-
icity. To solve the problem, several groups have tried to intro-
duce novel methods for removing surfactant molecules from
ultrasmall nanoparticles (under 50 nm) recently (Zhang et al.
2003; Salabat et al. 2008; Urata et al. 2009; Nazar et al. 2011;
Hollamby et al. 2009; Sun et al. 2009).
In this work, we prepared ORMOSIL nanoparticles using
normal micelle method and investigated the effect of the
presence of different surfactants including AOT and Tween
80 on the surface charge of the nanoparticles and cellular
uptake of dye-doped conjugated nanoparticles. The shape,
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size, and surface charge of the resulting nanoparticles were
characterized by transmission electron microscopy (TEM)
and Zetasizer Nano. We also report the development of
Herceptin-functionalized ORMOSIL nanoparticles as
nanoplatforms for targeting HER2-positive breast cancer
cells in vitro. Amino-active ORMOSIL nanoparticles syn-
thesized by various surfactants were conjugated with
Herceptin, and the platforms were utilized for active
targeting of SKBR3, a breast cancerous cell line with highly
expression of HER2 receptor, in vitro. For visualization and
demonstration of the process of active targeting in vitro, we
encapsulated Nile Red, an hydrophilic organic dye, in
ORMOSIL nanoparticles, the dye becomes suitable for
using in bioenvironments as an optical probe after encapsu-
lation (Qian et al. 2008), and used optical imaging by
fluorescence microscopy.
Herceptin-functionalized ORMOSIL nanoparticles are ap-
propriate for labeling HER2-positive breast cancer cells and
consequently differentiation of HER2-positive from HER2-
negative breast cancers clinically. In addition, it can be loaded
or linked with different therapeutic and diagnostic agents as well
as other nanoparticles such as magnetic or gold nanoparticles or
quantum dots and even amixing of these particles and used as a
vehicle for drug, gene, or nanoparticle delivery to breast cancer
cells. Figure 1 shows a schematic view of the bioconjugation
process of ORMOSIL nanoparticles with Herceptin.
2 Materials and methods
2.1 Materials
Surfactants AOT (98 %) and Tween 80 (viscous liquid), co-
surfactants 1-butanol (99.8 %), ORMOSIL precursors VTES
(97 %) and APTES (99 %), organic dye Nile Red (technical
grade), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC 98–100 %) were purchased from Sigma-Aldrich. All of
the above chemicals were used without any additional
purification unless noted. Breast cancer cell line SkBr3 was
purchased from Pasteur Institute of Iran. All cells were incu-
bated in RPMI-1640 medium (Sigma-Aldrich), supplemented
with 10 % fetal bovine serum (FBS, Sigma-Aldrich), 100
units/ml penicillin–streptomycin, and incubated at 37 °C in a
95 % humidified atmosphere containing 5 % CO2.
2.2 Synthesis of Nile Red-encapsulated amine-terminated
ORMOSIL nanoparticles
ORMOSIL nanoparticles, with or without Nile Red, were
synthesized based on the method described by Prasad’s
group. In separate experiments, the nanoparticles were syn-
thesized in the nonpolar core of two different micellar sys-
tems including of AOT/1-butanol/DMSO and Tween 80/1-
butanol/DMSO in deionized water. In a typical experiment,
for each sample, the micelles were prepared by dissolving
0.2 g of Aerosol OT or Tween 80 and 300 μl of 1-butanol in
10 ml of deionized water using magnetic stirring, forming
two different oil-in-water microemulsions. To each of the
microemulsion systems, 100 μl DMSO was added; for
preparing dye-doped nanoparticles, a 100 μl sample of clear
solution of Nile Red in DMSO (5 mM) was added, by
magnetic stirring, followed by addition 100 μl of neat
VTES. The resulting solutions were stirred for about 1 h.
Then, to initialize the polymerization reaction of the VTES
precursor and make the nanoparticles amine-terminated,
15 μl neat APTES was added. In each solution, the poly-
merization reaction was completed within the precipitated
nanoparticles by stirring for another 24 h at room tempera-
ture. For each solution of formed nanoparticles, dialysis
against deionized water was used for purification of the
nanoparticles using 12–14 kDa cutoff cellulose membrane
for 2 days to remove surfactants AOT, Tween 80, co-
surfactants 1-butanol, unreacted VTES and APTES, and
free Nile Red. The remained surfactant molecules were
removed by continuing dialyzing for 4, 6, and 8 days.
Each dialyzed solution was then filtered through 0.22 μm
Fig. 1 The schematic view of
the bioconjugation of Nile Red-
encapsulated ORMOSIL
nanoparticles with Herceptin
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cutoff membrane filter and stored at 4 °C for later experi-
ments. The nanoparticles prepared with AOT were named
AOTORM and the particles prepared with Tween 80 named
TWORM.
2.3 Characterization of the nanoparticles
2.3.1 Transmission electron microscopy and dynamic light
scattering
To determine the morphology and the size of the resulting
nanoparticles, transmission electron microscopy pictures
were taken on a PHILIPS CM120 electron microscope
operating at an accelerating voltage of 120 kV. A drop of
the nanoparticles dispersed in water was put on a copper
grid coated with Formvar solution. The pictures were taken
after the grid dried.
The nanoparticles size was also determined by Zetasizer
Nano (Malvern Instr, UK). The charge of the nanoparticles
was quantified as zeta potential (Z.P) using a Zetasizer Nano
(Malvern Instr, UK). Measurements were performed in de-
ionized water with pH=8.
2.3.2 Zeta potential measurements
After the formation of the nanoparticles, Aerosol OT or
Tween 80 surfactants and co-surfactant 1-butanol were re-
moved gradually by dialysis the solution against double-
distilled water in 12- to 14-kDa cutoff cellulose membranes
then the dialyzed solutions were filtered through a 0.2-μm
cutoff membrane filter and used for zeta potential measure-
ments. The surface charge of nanoparticles was recorded
before dialysis, after 2, 4, 6, and 8 days dialysis by using
zeta potential measurements. In addition to nanoparticles,
the zeta potential of AOT and Tween 80 micelles were
recorded after micelle formation.
2.4 Bioconjugation of amine-terminated ORMOSIL
nanoparticles with Herceptin
In separate experiments, the AOTORM and TWORM
nanoparticles were conjugated to Herceptin (Roche,
Switzerland) using a water-soluble carbodiimide, EDC.
Herceptin powder was dialyzed in MES buffer (0.1 M, pH
6.5) and the concentration was determined with a UV–
Visible spectrophotometer (Libra s22, Biochrom). To form
linkages between carboxylates of Herceptin and primary
amines of ORMOSIL nanoparticles, the reactions of EDC
amide bond formation was used (Fig. 1). Because the effec-
tive pH for formation of EDC-mediated amide bond reaction
is between pH4.5 and 7.5, we used MES buffer (0.1 M, pH
6.5) for conjugation reaction. EDC is more effective for
activation of carboxyl groups; therefore, we added 50 μl
EDC (0.1 M) to 200 μl Herceptin (2 mg/ml) solution in
MES buffer. After 1 h incubation in room temperature, 1 ml
ORMOSIL nanoparticle solution was added to active pro-
tein and incubated for 2 h at room temperature to allow the
free amine groups of the nanoparticles to covalently bond to
the carboxyl groups of Herceptin. Certain amounts of gly-
cine were added to the solutions of conjugated nanoparticles
to block remaining active groups. After purification, all
samples were stored at 4 °C for additional cell experiments.
2.5 Cell culture and cellular imaging
SKBR3 cells, a breast cancer cell line with overexpression
of HER2 receptors, were cultivated in RPMI 1640 media
with 10 % FBS, 1 % penicillin, and 1 % streptomycin. One
day before treatment with the nanoparticles, cells were seed-
ed in eight-well glass slide (each well 3×104 cells).
During the treatment, the separate wells were incubated
with 50 μl of different samples including dye-doped
conjugated ORMOSIL (either AOTORM or TWORM)
nanoparticles (2 mg/ml), dye-doped non-conjugated
ORMOSIL (either AOTORM or TWORM) nanoparticles
(2 mg/ml), Herceptin solution (10 μg/ml) followed by
Sheep Anti Human IgG-FITC (0.2 μg/ml). After adding
each sample, the cell incubation process lasted for 2 h at
37 °C in a humidified 5 % CO2 atmosphere. Then, the cells
were washed thrice with PBS buffer and directly imaged
with a Fluorescence Microscopy (BX51, Olympus). The
used excitation and emission wavelengths for fluorescent
imaging were, respectively, 570 and 640 nm.
3 Results and discussion
3.1 Characterizations of ORMOSIL nanoparticles
ORMOSIL nanoparticles using normal micelle microemulsion
formed by AOT or Tween 80 were synthesized with
narrow size distributions and spherical shape, as shown
by TEM images and dynamic light scattering (DLS) in
Figs. 2 and 3, and named AOTORM and TWORM, re-
spectively. Figure 2a shows TEM images of AOTORM
nanoparticles with diameter around 25–50 nm; the parti-
cles have an average hydrodynamic diameter of 35 nm
(Fig. 3b). Figure 2b shows that TWORM nanoparticles
have a diameter of 15–20 nm and their average hydrody-
namic diameter is 10.9 nm (Fig. 3d).
Normal microemulsion is a common method for synthesis
of spherical and highly uniform ORMOSIL nanoparticles.
In this process, the micelles or nanodroplets (nanoreactors)
prepared in the microemulsion system provide surrounded
cages for hydrolysis and condensation of ORMOSIL precur-
sors. Because the size of particles is limited within the
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micelles, one of the most significant factors that controls the
size and uniformity of the resulting particles is the volume of
these self-assembled templates.
We found that one of the important factors determining
the size distribution of the micelles and ORMOSIL
nanoparticles is intrinsic properties of the surfactant espe-
cially solubility of the surfactant. The more water-soluble is
the surfactant, the more monodisperse micelles and
ORMOSIL nanoparticles can be achieved. Figure 3a shows
the DLS result of AOT/water/DMSO micellar system; it is
evident that low solubility of AOT surfactant has caused
preparation of micelles with a wide variety of sizes from
200 to 900 nm. As a result of this polydisperse micellar
system, the size of the nanoparticles (AOTORM) synthe-
sized in the core of these micelles is relatively polydis-
perse (Figs. 2a and 3b).
However, because of the high solubility of Tween 80 in
water, the micelles prepared in Tween 80/water/DMSO
microemulsion are highly monodisperse with average hy-
drodynamic size of 11.7 nm (Fig. 3c) that have led to highly
monodisperse nanoparticles with average hydrodynamic
size of 10.9 nm (Fig. 3d).
To make the nanoparticles fluorescent, a hydrophobic
fluorophore, Nile Red, was encapsulated into the silica
matrix of AOTORM and TWORM. Since, Nile Red is not
water-soluble, its molecules tend to nonpolar core of normal
micelles. Once the condensation of ORMOSIL precursor,
VTES, starts, the dye molecules are entrapped into
ORMOSIL nanoparticles and will not be release. The aver-
age hydrodynamic size of the dye-doped particles was de-
termined by DLS. It was seen that after entrapment of the
dye, the size of the particles was increased from 35 to 53 nm
for AOTORM nanoparticles and from 10.9 to 43 nm for
TWORM nanoparticles that can confirm successful encap-
sulation of the dye (Fig. 4, Table 1).
To determine fluorescent properties of Nile Red after en-
capsulation of the organic dye within silica matrix, emission
spectra of free Nile Red and Nile Red encapsulated in
ORMOSIL nanoparticles were recorded by fluorescent spec-
troscopy. It was found that the excitation and emission wave-
length of Nile Red doped in ORMOSIL nanoparticles were
Fig. 2 TEM images of ORMOSIL nanoparticles synthesized using
AOT (AOTORM NPs) (a), and ORMOSIL nanoparticles synthesized
using Tween 80 (TWORM NPs) (b)
Fig. 3 Average hydrodynamic size distribution obtained by DLS from AOT micelles (a), AOTORM nanoparticles (b), Tween 80 micelles (c), and
TWORM nanoparticles (d) with the mean size of 749, 35, 11.7, and 10.9 nm, respectively
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570 and 640 nm, respectively, than are similar to the
excitation and emission wavelength of free Nile Red
(Fig. 5).
3.2 Effect of surfactant molecules on the surface charge
of the particles
The surface properties and functionalization of silica
nanoparticles play a critical role in biomedical applications.
Based on DLVO theory, colloidal stability of the nanoparticles
strongly depends on electrostatic charges and steric effects of
the surface of nanoparticles (Ueno et al. 2008). The surface
modification provides functional groups on the surface of
silica nanoparticles that can be advantageous for their colloi-
dal stability and can be applied for bioconjugation.
Furthermore, surface functionalization of silica particles is
important in their interaction with biological environments
as well as their cellular uptake and cytotoxicity. The zeta
potential (Z.P) of a particle is a representative of overall
surface charge of the particle in the medium in which the
particle is dispersed. The net charge at the nanoparticle surface
is an accumulation of all charges present on the surface. There
are various parameters that can affect Z.P of the nanoparticles
such as presence of surfactant, connectivity of the solution,
and pH (Bagwe et al. 2004; Wang et al. 2008). In terms of
ORMOSIL nanoparticles, the factors that incorporate in over-
all charge are anionic silanol groups, cationic primary amine
groups, and anionic or nonionic surfactant molecules. Silanol
groups and surfactant molecules make the surface anionic
while amine groups add cationic charges to the surface.
To demonstrate the impact of the presence of surfactant
molecules on surface charge of ORMOSIL nanoparticles,
we did a study of surface charge of the nanoparticles by Z.P
measurements of AOTORM and TWORM nanoparticles.
We used dialysis as a method for removing surfactant mol-
ecules gradually. Due to anionic hydrocarbon chains of
AOT surfactant, the Z.P of AOT micelles is −44 mV. On
the other hand, there is no ionic hydrocarbon chain in Tween
80; as a result, the Z.P of Tween 80 micelles is −4 mV
(Fig. 6). Figure 7a, b shows Z.P of AOTORM and TWORM
nanoparticles before dialysis (column 0) and after 2, 4, 6,
and 8 days dialysis. AOTORM nanoparticles with no dial-
ysis show Z.P of −89.9 mV (Fig. 7a), and Z.P of TWORM
nanoparticles with no dialysis is −55 (Fig. 7b). Figure 7a, b
shows a significant reduction in anionic charge of
AOTORM and TWORM nanoparticles after 2 and 4 days
dialysis. The amount of zeta potential for AOTORM NPs
after 2, 4, 6, and 8 days dialysis is −57.2, −32.2, −23.3,
and −21.5 mV, respectively, and for TWORM NPs after 2,
4, 6, and 8 days dialysis is, respectively, −3.7, −1.5, −1.2,
and −1.1 mV.
Fig. 4 Average hydrodynamic
size distribution obtained by
DLS from dye-doped
AOTORM (a) and TWORM
(b) nanoparticles with the mean
size of 53 and 43 nm,
respectively
Table 1 A comparisons of the size of ORMOSIL nanoparticles before
and after the dye encapsulation
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The reduction in both samples is mostly related to the
reduction of surfactant molecules from the surface of the
nanoparticles by dialysis. As dialysis continues, more sur-
factant molecules are removed which results in decreasing
overall anionic charge of AOTORM nanoparticles.
However, the efficacy of dialysis for removing remained
AOT decreases after 4 days, and therefore, the overall
charge of AOTORM nanoparticles remains constant in 6
and 8 days dialysis. This is the case for TWORM
nanoparticles as well. It is evident that before removing
the surfactant molecules completely, the surface charge of
the nanoparticles is strongly dependent on the charges of
surfactant molecules. By decreasing the number of surfac-
tant molecules from the surface during dialysis, the zeta
potential of the nanoparticles is changing from highly neg-
ative to less negative amount for AOT and less negative to
positive amounts for Tween 80. The results reveal that the
remained surfactant molecules have a very strong impact on
the surface charge of nanoparticles and can cause a misun-
derstanding of actual charge of nanoparticles. In addition,
data show that dialysis is an appropriate method to recover
the nanoparticles from microemulsions effectively and ef-
fortlessly. All nanoparticles were dispersed in deionized
water and all Z.Ps were measured at pH=8.
3.3 Active cell targeting
To make a nanoplatform for breast cancer specific targeting
in vitro or in vivo, the nanoparticles must be conjugated
with a biomoiety that recognizes these cells specifically.
Among a number of crosslinker molecules, using the
water-soluble carbodiimide EDC is a typical bioconjugation
reaction to attach biomolecules to different particles. EDC
provides covalent linkages between primary amines and
carboxylic group. It activates the carboxyl groups of a
carboxyl-containing molecule and forms an unstable inter-
mediate compound that can be either hydrolyzed or linked
with primary amines of an amine-containing molecule. This
reaction leads to formation of stable amide bonds and can be
followed for surface functionalization of nanoparticles
(Sperling and Parak 2010).
Herein, we present the conjugation of ORMOSIL
nanoparticles with Herceptin using EDC conjugation reac-
tion. EDC was used to activate carboxylic group of
Herceptin. This reaction leads to formation of Herceptin-
functionalized ORMOSIL nanoparticles that enable to
target HER2 receptors. Since SKBR3 human breast cancer
cell line is a popular breast cancerous cell line with
overexpression of HER2, it is an appropriate model to show
active targeting by Herceptin-functionalized nanoparticles.
To confirm active targeting, we took fluorescent images
of SKBR3 cells treated with various samples. In order to
investigate the expression of HER2 receptor on the mem-
brane of SKBR3 cells, we first added an appropriate con-
centration of Herceptin solution to the cells and then used a
secondary antibody labeled with FITC (Sheep Anti Human
IgG-FITC) against Herceptin for active staining of cell
membrane of SKBR3 cells. Figure 8a shows that the cells
treated with no sample have no autofluorescent. However,
the cells that were treated with Herceptin as well as the
secondary antibody labeled with FITC show strong green
color emitted from FITC (Fig. 8b). These results confirm
presence of HER2 receptor on the membrane of our cells. It
is because Herceptin has made linkages to HE2 receptors
and the secondary antibody has linked to Herceptin and
stained the cells.
Figure 8c shows the images obtained from SKBR3 after
treatment with dye-doped, amine-active, and non-
conjugated TWORM NPs for 2 h. As seen in this image,
the visible red fluorescence emitted from treated cells show
that the cell membranes are stained with these particles that
confirms nonspecific bandings between TWORM NPs and
SKBR3 cell line. Figure 8e shows the florescent images
Fig. 5 Fluorescent spectrum of Nile Red dissolved in DMSO and Nile
Red encapsulated in ORMOSIL nanoparticles
Fig. 6 The amount of zeta potential of AOT and Tween 80 micelles
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taken from the cells after being treated with dye-doped,
amine-active, and non-conjugated AOTORM NPs for 2 h.
The data confirm that there is no visible red fluorescence
from the images of the cells treated with the dye-doped
AOTORM NPs indicating that none of these particles has
significant nonspecific bandings with the cell membranes.
In general, it is expected that amino-functionalized
ORMOSIL nanoparticles have a tendency to go to the
surface of the cells due to electrostatic interactions between
positive charges, derived from positive amino groups on the
surface of the nanoparticles, and negative charges of cell
membrane. However, it should be noted that it is the overall
Fig. 7 The amount of zeta
potential for AOTORM
nanoparticles with no dialysis
(column 0 day) and after 2, 4, 6,
and 8 days dialysis (a), and the
amount of zeta potential for
TWORM nanoparticles with no
dialysis (column 0 day) and after
2, 4, 6, and 8 days dialysis (b)
Fig. 8 Fluorescent images of
SKBR3 cells treated with no
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surface charge of the nanoparticles that is mostly responsi-
ble for electrostatic interactions between the particles and
the cell membrane. The overall surface charge of TWORM
NPs is −3.7 mVand not so negative to prevent the formation
of nonspecific bonding between these particles and the cell
membranes. On the other hand, in terms of AOTORM NPs,
the negative charges of remained AOT surfactant molecules
and silanol groups on the surface of these nanoparticles
shrink the efficiency of positive charges produced by amine
groups and make the surface charge of these particles very
negative, −57.2 mV. Therefore, by doing a simple washing
by PBS buffer, most of the nonspecific bindings between the
cell membrane and the nanoparticles can be removed. These
results show that the intrinsic properties of surfactant used
for synthesis of ORMOSIL NPs can have a critical role in
electrostatic interactions between the surface of ORMOSIL
NPs and the cell membrane.
Figure 8d, f, respectively, shows fluorescent microscopy
images of SKBR3 cells stained with dye-doped TWORM
and AOTORM nanoparticles both conjugated with
Herceptin.
Figure 8d shows that the intensity of red fluorescent from
the cells stained with Herceptin-conjugated TWORM NPs is
similar to the cells stained with non-conjugated TWORM
NPs. Tween 80 is not a dialyzable surfactant; therefore, it
cannot be removed from the nanoparticles by short time
dialysis which results in the existence of high concentration
of surfactant on the surface of the particles that can produce
many nonspecific interactions.
These surfactant molecules remained on the surface of
TWORM nanoparticles can even prevent conjugation of
primary amine groups of the nanoparticles with Herceptin;
consequently, there is no significant difference between the
stained cells with non-conjugated TWORM NPs and
Herceptin-conjugated TWORM NPs.
Figure 8f shows the images taken from SKBR3 after treat-
ment with dye-doped Herceptin-conjugated AOTORM NPs
for 2 h. As seen in the images, in comparison to non-
conjugated AOTORM NPs, there is strong visible red fluo-
rescence from the images of the cells treated with conjugated
AOTORM NPs that confirms significant specific targeting.
It can be seen that after 2 h of incubation with SKBR3,
Herceptin-functionalized AOTORM NPs have produced
strong specific bindings with extracellular domain of
HER2 receptor on the cell membrane of SKBR3 that con-
firms efficient active targeting (Fig. 8f). It is evident that the
functionalized nanoparticles are localized on the cell mem-
brane by HER2 receptors.
In comparison to Tween 80, AOT is relatively removable
by dialysis. As a result, after dialysis, most of the surfactant
molecules used for synthesis of AOTORM NPs are removed
that makes the surface of the particles appropriate for con-
jugation of Herceptin with amine groups and the negative
chains of remained AOT molecules can be efficient to
prevent strong nonspecific bandings.
Hence, we can conclude that the Herceptin-conjugated
AOTORM NPs are able to distinguish and target HER2-
positive cancerous cells from normal cells and therefore
enable differentiation between HER2 normal and HER2
overexpressing human breast cancer cells in vitro. This
application can be useful for determination of treatment
method especially based on Herceptin targeting or other
modalities. Moreover, our results show that the type of the
surfactant used for formation of ORMOSIL NPs can play a
significant role in interaction of the particles and the cell
membrane.
4 Conclusion
Monodispersed ORMOSIL nanoparticles entrapped with a
hydrophobic organic dye, Nile Red, were synthesized and
characterized. In order to investigate the impact of the
presence of surfactant molecules on the surface chemistry
and surface charge of the nanoparticles, two different sur-
factants (AOT, Tween 80) were used as templates for for-
mation of three different ORMOSIL nanoparticles. The
results confirmed huge impact of these surfactants on the
surface charge of the nanoparticles. Each of the
nanoparticles had conjugated with Herceptin, to specific
delivery of fluorescent nanoparticles to SKBR3 cells, as a
model for HER2 overexpressing breast cancer. We found
that the efficiency bioconjugation can be affected by pres-
ence of surfactant molecules on the surface of ORMOSIL
nanoparticles. ORMOSIL nanoparticles conjugated with
Herceptin are excellent candidates for determining whether
breast cancer is HER2 positive or Her2 negative. This is
important for determination of treatment strategy for breast
cancer in clinics. Herceptin-functionalized ORMOSIL
nanoparticles are also appropriate vehicles for targeted
drug/gene delivery to breast cancer cells in the future works.
References
Bagwe RP, Yang C, Hilliard LR, Tan W (2004) Optimization of dye-
doped silica nanoparticles prepared using a reverse microemulsion
method. Langmuir 20(19):8336–8342
Bardhan R, Chen W, Perez Torres C, Bartels M, Huschka RM, Zhao
LL, Morosan E, Pautler RG, Joshi A, Halas NJ (2009) Nanoshells
with targeted simultaneous enhancement of magnetic and optical
imaging and photothermal therapeutic response. Adv Funct Mater
19(24):3901–3909
Bharali D, Klejbor I, Stachowiak E, Dutta P, Roy I, Kaur N, Bergey E,
Prasad P, Stachowiak M (2005) Organically modified silica
nanoparticles: a nonviral vector for in vivo gene delivery and
expression in the brain. Proc Natl Acad Sci U S A 102(32):11539
Active targeting of HER2-positive breast cancer cells 35
Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting
schemes for nanoparticle systems in cancer therapeutics. Adv
Drug Deliv Rev 60(15):1615–1626
Ciriminna R, Sciortino M, Alonzo G, Schrijver A, Pagliaro M (2011)
From molecules to systems: sol-gel microencapsulation in silica-
based materials. Chem Rev 111(2):765–789
Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S,
Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S (2010)
HER2 targeting as a two-sided strategy for breast cancer diagnosis
and treatment: Outlook and recent implications in nanomedical
approaches. Pharmacol Res 62(2):150–165
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvi-
ronment: passive and active tumor targeting of nanocarriers for
anti-cancer drug delivery. J Control Release 148(2):135–146
Darbandi M, Thomann R, Nann T (2005) Single quantum dots in silica
spheres bymicroemulsion synthesis. ChemMater 17(23):5720–5725
Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S,
Langer RS, Farokhzad OC (2007) Targeted nanoparticles for
cancer therapy. Nano Today 2(3):14–21
Han Y, Jiang J, Lee SS, Ying JY (2008) Reverse microemulsion-
mediated synthesis of silica-coated gold and silver nanoparticles.
Langmuir 24(11):5842–5848
Harries M, Smith I (2002) The development and clinical use of
trastuzumab (Herceptin). Endocr Relat Cancer 9(2):75
Hollamby MJ, Eastoe J, Chemelli A, Glatter O, Rogers S, Heenan RK,
Grillo I (2009) Separation and purification of nanoparticles in a
single step. Langmuir 26(10):6989–6994
Kim S, Ohulchanskyy T, Pudavar H, Pandey R, Prasad P (2007a)
Organically modified silica nanoparticles co-encapsulating
photosensitizing drug and aggregation-enhanced two-photon ab-
sorbing fluorescent dye aggregates for two-photon photodynamic
therapy. J Am Chem Soc 129(9):2669–2675
Kim S, Pudavar H, Bonoiu A, Prasad P (2007b) Aggregation-enhanced
fluorescence in organically modified silica nanoparticles: a novel
approach toward high-signal-output nanoprobes for two-photon
fluorescence bioimaging. Adv Mater 19(22):3791–3795
Kim S, Ohulchanskyy T, Bharali D, Chen Y, Pandey R, Prasad P
(2009) Organically modified silica nanoparticles with intraparticle
heavy-atom effect on the encapsulated photosensitizer for en-
hanced efficacy of photodynamic therapy. J Phys Chem C
113(29):12641–12644
Klejbor I, Stachowiak E, Bharali D, Roy I, Spodnik I, Morys J, Bergey
E, Prasad P, Stachowiak M (2007) ORMOSIL nanoparticles as a
non-viral gene delivery vector for modeling polyglutamine in-
duced brain pathology. J Neurosci Methods 165(2):230–243
Kumar R, Roy I, Ohulchanskyy T, Goswami L, Bonoiu A, Bergey E,
Tramposch K, Maitra A, Prasad P (2008) Covalently dye-linked,
surface-controlled, and bioconjugated organically modified silica
nanoparticles as targeted probes for optical imaging. Acs Nano
2(3):449–456
Kumar R, Roy I, Ohulchanskky T, Vathy L, Bergey E, Sajjad M,
Prasad P (2010) In vivo biodistribution and clearance studies
using multimodal organically modified silica nanoparticles. Acs
Nano 4(2):699–708
Law W, Yong K, Roy I, Xu G, Ding H, Bergey E, Zeng H, Prasad P
(2008) Optically and magnetically doped organically modified
silica nanoparticles as efficient magnetically guided biomarkers
for two-photon imaging of live cancer cells†. J Phys Chem C
112(21):7972–7977
Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Narimatsu S,
Monobe Y, Imazawa T, Tsunoda S, Tsutsumi Y (2010) The effect
of surface modification of amorphous silica particles on NLRP3
inflammasome mediated IL-1 [beta] production, ROS production
and endosomal rupture. Biomaterials 31(26):6833–6842
Nabeshi H, Yoshikawa T, Arimori A, Yoshida T, Tochigi S, Hirai T,
Akase T, Nagano K, Abe Y, Kamada H (2011) Effect of surface
properties of silica nanoparticles on their cytotoxicity and cellular
distribution in murine macrophages. Nanoscale Res Lett 6(1):93
Nazar MF, Myakonkaya O, Shah SS, Eastoe J (2011) Separating
nanoparticles from microemulsions. J Colloid Interface Sci
354(2):624–629
Nel AE, Mädler L, Velegol D, Xia T, Hoek EMV, Somasundaran P,
Klaessig F, Castranova V, Thompson M (2009) Understanding
biophysicochemical interactions at the nano–bio interface. Nat
Mater 8(7):543–557
Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, Pandey
RK, Oseroff AR, Prasad PN (2007) Organically modified silica
nanoparticles with covalently incorporated photosensitizer for
photodynamic therapy of cancer. Nano Lett 7(9):2835–2842
Osseo-Asare K, Arriagada F (1990) Preparation of SiO2 nanoparticles
in a non-ionic reverse micellar system. Colloids Surf 50:321–339
Qian J, Li X, Wei M, Gao X, Xu Z, He S (2008) Bio-molecule-
conjugated fluorescent organically modified silica nanoparticles
as optical probes for cancer cell imaging. Opt Express
16(24):19568–19578
Qian J, Chen Q, Cai F, Kong S, Ho H, He S (2009) Quantum-dots-
doped ORMOSIL nanoparticles as optical probes for total internal
reflection fluorescence imaging of cancer cells. IEEE J Sel Top
Quantum Electron 15(5):1374–1379
Qian J, Fu T, Zhan Q, He S (2010) Using some nanoparticles as
contrast agents for optical bioimaging. IEEE J Sel Top Quantum
Electron 16(3):672–684
Roy I, Ohulchanskyy T, Pudavar H, Bergey E, Oseroff A, Morgan J,
Dougherty T, Prasad P (2003) Ceramic-based nanoparticles
entrapping water-insoluble photosensitizing anticancer drugs: a
novel drug- carrier system for photodynamic therapy. J Am
Chem Soc 125(26):7860–7865
Salabat A, Eastoe J, Vesperinas A, Tabor RF, Mutch KJ (2008)
Photorecovery of nanoparticles from an organic solvent.
Langmuir 24(5):1829–1832
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL
(1987) Human breast cancer: correlation of relapse and survival with
amplification of the HER-2/neu oncogene. Science 235(4785):177–
182
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L
(2001) Use of chemotherapy plus a monoclonal antibody against
HER2 for metastatic breast cancer that overexpresses HER2. N Engl
J Med 344(11):783–792. doi:10.1056/NEJM200103153441101
Sperling R, Parak W (2010) Surface modification, functionalization and
bioconjugation of colloidal inorganic nanoparticles. Philosophical
transactions of the royal society a: mathematical. Phys Eng Sci 368
(1915):1333
Stober W, Fink A, Bohn E (1968) Controlled growth of monodisperse
silica spheres in the micron size range. J Colloid Interface Sci
26(1):62–69
Sun X, Tabakman SM, Seo WS, Zhang L, Zhang G, Sherlock S,
Bai L, Dai H (2009) Separation of nanoparticles in a density
gradient: FeCo@ C and gold nanocrystals. Angew Chem
121(5):957–960
Ueno K, Inaba A, Kondoh M, Watanabe M (2008) Colloidal stability
of bare and polymer-grafted silica nanoparticles in ionic liquids.
Langmuir 24(10):5253–5259
Urata C, Aoyama Y, Tonegawa A, Yamauchi Y, Kuroda K (2009)
Dialysis process for the removal of surfactants to form col-
loidal mesoporous silica nanoparticles. Chem Commun
34:5094–5096
Viswanathan K (2011) Preparation and characterization of fluorescent
silica coated magnetic hybrid nanoparticles. Colloid Surface
Physicochem Eng Aspect 386:11–15
Wang L, Zhao W, Tan W (2008) Bioconjugated silica nanoparticles:
development and applications. Nano Res 1(2):99–115
36 V. Shirshahi et al.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett J (2003)
Expression of the HER1–4 family of receptor tyrosine kinases
in breast cancer. J Pathol 200(3):290–297
Xia T, KovochichM, LiongM,MengH, Kabehie S, George S, Zink JI, Nel
AE (2009) Polyethyleneimine coating enhances the cellular uptake of
mesoporous silica nanoparticles and allows safe delivery of
siRNA and DNA constructs. ACS Nano 3(10):3273–3286
Yong K, Roy I, Swihart M, Prasad P (2009) Multifunctional
nanoparticles as biocompatible targeted probes for human cancer
diagnosis and therapy. J Mater Chem 19:4655
Zhang R, Liu J, Han B, He J, Liu Z, Zhang J (2003) Recovery of
nanoparticles from (EO) 8 (PO) 50 (EO) 8/p-xylene/H2O
microemulsions by tuning the temperature. Langmuir 19(21):8611–
8614
Active targeting of HER2-positive breast cancer cells 37
